Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
153.4 USD | +2.09% | +6.67% | -20.13% |
05-02 | Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed | MT |
05-02 | Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.13% | 19.01B | |
+24.32% | 48.09B | |
+46.90% | 40.62B | |
-2.44% | 40.43B | |
-6.95% | 28.36B | |
+7.48% | 24.89B | |
+29.13% | 12.09B | |
-0.29% | 11.88B | |
-0.32% | 11.8B | |
+17.76% | 11.45B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Insider Sell: Alnylam Pharmaceuticals